Partial sleep deprivation therapy combined with sertraline affects subjective sleep quality in major depressive disorder.
OBJECTIVE
Earlier studies have shown an association between mood disorders and sleep regulation. Total or partial sleep deprivation was demonstrated to have rapid antidepressive effects in depression. Depressive symptoms recur after one night of recovery sleep, but relapse is less when patients are receiving medication. In this study, we examined the subjective sleep quality changes with the antidepressive therapy using partial sleep deprivation plus sertraline and sertraline monotherapy in patients with major depressive disorder.


METHODS
Thirteen patients received six partial sleep deprivation therapies in addition to sertraline; the sleep schedule on deprivation nights started at 11:00 p.m. and ended at 3:00 a.m. Eleven patients were treated with sertraline monotherapy as a control group. Six nights of partial sleep deprivation were completed in the first two weeks. Subjective sleep quality was evaluated with the Pittsburgh Sleep Quality Index (PSQI); depression and the accompanying anxiety were also assessed at baseline and at the end of the fourth week.


RESULTS
The late partial sleep deprivation (LPSD) group showed less increase in estimated sleep duration and less significant improvement in subjective sleep quality than the control group. Although decreased sleep latency and increased sleep efficiency are associated with the sleep deprivation, contrary results were found in our study.


CONCLUSIONS
In conclusion, changes in subjective sleep quality could occur relative to the combined partial sleep deprivation therapy and to pharmacotherapy and must be differentiated from the rapid effects of sleep deprivation therapy and objective polysomnographic measures.
Caliyurt
Okan
O
Psychiatry Department Trakya University School of Medicine, 22030 Edirne, Turkey. caliyurt@hotmail.com
Guducu
Funda
F
D000328:Adult; D000928:Antidepressive Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003865:Major Depressive Disorder / Q000503:physiopathology* / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020280:Sertraline / Q000008:administration & dosage*; D012890:Sleep / Q000502:physiology*; D012892:Sleep Deprivation; D016896:Treatment Outcome
D000928:Antidepressive Agents; D020280:Sertraline